Genmab Reports Nine-Month Revenue of $3.24 Billion, Maintains 2026 Guidance
Revenue rose 22% year over year to $3.24 billion for the nine months ended September 30, 2026. Genmab reported operating profit of $986 million and net profit of $698 million.
Genmab A/S released its interim report for the nine months ended September 30, 2026, showing revenue of $3.24 billion, a 22% increase compared to the same period in 2025. Royalty revenue reached $2,699 million, driven by higher net sales of DARZALEX and Kesimpta, while global net sales of EPKINLY/TEPKINLY reached $491 million. The company reported an operating profit of $986 million and a net profit of $698 million for the nine-month period. Management confirmed that the company is maintaining its previously published 2026 financial guidance.
The report also noted increased investment in the product pipeline, including the advancement of Rina-S and petosemtamab.